<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Tue, 23 Dec 2025 00:50:30 +0000</lastBuildDate>
    <item>
      <title>#1 [85/100] INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41427951/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41427951/</guid>
      <dc:creator>Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, et al.</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 85/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a randomized Phase II/III study evaluating a novel combination therapy in a relevant patient population, with the potential for significant clinical impact on treatment paradigms in recurrent/metastatic head and neck squamous cell carcinoma.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Clinical cancer research : an official journal of the American Association for Cancer Research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/1078-0432.CCR-25-1197'&gt;10.1158/1078-0432.CCR-25-1197&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41427951/'&gt;41427951&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Feladilimab, an inducible T-cell co‚Äëstimulatory receptor agonist, demonstrated clinical activity in combination with pembrolizumab in a Phase I head and neck squamous cell carcinoma (HNSCC) expansion cohort, prompting further evaluation in patients in this setting. PATIENTS AND METHODS: INDUCE-3 (NCT04128696) was a randomized, double-blind, Phase II/III study in first-line programmed death-ligand 1-positive recurrent and/or metastatic HNSCC patients. A 2-in-1 adaptive design was implemented, with an option to expand the Phase II study into a Phase III confirmatory study. Patients were randomized 1:1 to receive feladilimab plus pembrolizumab or placebo plus pembrolizumab; up to 35 cycles of treatment for approximately 2 years. Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS). RESULTS: The study enrolled 315 patients. Following review of unblinded interim data in 140 patients, an Independent Data Monitoring Committee recommended stopping patient accrual based on prespecified criteria. Existing patients discontinued feladilimab or placebo. Pembrolizumab treatment continued until prespecified stopping criteria were met. This study demonstrated no evidence of an effect in favor of feladilimab plus pembrolizumab, with an adjusted HR of 1.51 for OS and 1.40 for PFS (median OS: 44.1 weeks [95% confidence interval (CI): 35.9-NA]; median PFS: 10.1 weeks [95% CI: 9.1-15.0]) versus placebo plus pembrolizumab (median OS: not reached; median PFS: 16.0 weeks [95% CI: 14.3-26.1]). The incidence of treatment-related adverse events was higher in the placebo group. CONCLUSIONS: This analysis does not support the combination of feladilimab plus pembrolizumab due to lack of superiority over placebo plus pembrolizumab.</description>
    </item>
    <item>
      <title>#2 [75/100] Efficacy and safety of Mepitel film for radiodermatitis: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41420160/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41420160/</guid>
      <dc:creator>Ren X, Wang H, Liu J, Yuan Y, Wu T, Zhang H, Yang D, Yan Y, Xu Y, Wei F</dc:creator>
      <pubDate>Fri, 19 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis includes a substantial number of studies (27) and a large patient population (2,313), providing important insights into the efficacy of Mepitel film for radiodermatitis, which has clinical relevance in the management of cancer treatment side effects.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ren X, Wang H, Liu J, Yuan Y, Wu T, Zhang H, Yang D, Yan Y, Xu Y, Wei F&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMC cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1186/s12885-025-15465-2'&gt;10.1186/s12885-025-15465-2&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-19&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41420160/'&gt;41420160&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To evaluate the effects of Mepitel film on the prevention and treatment of radiodermatitis. METHODS: We conducted a systematic search across multiple databases, including PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and SinoMed Database, from their inception until August 6, 2024. We identified randomized controlled trials (RCTs) or controlled clinical trials that assessed the effects of Mepitel film on radiodermatitis. The risk of bias was evaluated using the Revised Cochrane Risk-of-Bias tool for randomized trials (RoB2). Traditional meta-analysis was performed using RevMan 5.3 and Stata 14.0 software. RESULTS: A total of 27 studies involving 2,313 cancer patients were included. The pooled analysis indicated that Mepitel significantly reduced the incidence of radiation dermatitis (OR‚Äâ=‚Äâ0.28, 95%CI 0.16 to 0.50, I2‚Äâ=‚Äâ67%, P‚Äâ&lt;‚Äâ0.0001) compared to the control groups. In the subgroup analysis by cancer type, Mepitel reduced the incidence of radiation dermatitis in nasopharyngeal carcinoma (OR‚Äâ=‚Äâ0.25, 95%CI 0.13 to 0.46, I2‚Äâ=‚Äâ0%, P‚Äâ&lt;‚Äâ0.0001), breast cancer (OR‚Äâ=‚Äâ0.42, 95%CI 0.26 to 0.68, I2‚Äâ=‚Äâ24%, P‚Äâ=‚Äâ0.0004), and various malignancies (OR‚Äâ=‚Äâ0.10, 95%CI 0.06 to 0.16, I2‚Äâ=‚Äâ0%, P‚Äâ&lt;‚Äâ0.00001). Mepitel use was also associated with a lower incidence of moderate and severe skin injury in radiotherapy patients (RTOG grade II OR‚Äâ=‚Äâ0.26, 95%CI 0.16 to 0.42, P‚Äâ&lt;‚Äâ0.00001; RTOG grade III OR‚Äâ=‚Äâ0.19, 95%CI 0.12 to 0.30, P‚Äâ&lt;‚Äâ0.00001; RTOG grade IV OR‚Äâ=‚Äâ0.10, 95%CI 0.03 to 0.36, P‚Äâ=‚Äâ0.0005), as well as a reduction in the severity of radiation-induced skin damage (combined RISRAS score, MD= -0.74 95% CI -1.02 to -0.46, I2‚Äâ=‚Äâ95%, P‚Äâ&lt;‚Äâ0.00001; researcher RISRAS score MD= -0.47 95% CI -0.67 to -0.27, I2‚Äâ=‚Äâ90%, P‚Äâ&lt;‚Äâ0.00001; and patient RISRAS score MD= -1.19 95% CI -1.33 to -1.05, I2‚Äâ=‚Äâ39%, P‚Äâ&lt;‚Äâ0.00001). Additionally, patients treated with Mepitel experienced fewer cases of moist desquamation (OR‚Äâ=‚Äâ0.46, 95%CI 0.25 to 0.83, I2‚Äâ=‚Äâ58%, P‚Äâ=‚Äâ0.010), and shorter healing times (MD= -4.73, 95%CI -7.16 to -2.30, I2‚Äâ=‚Äâ98%, P‚Äâ=‚Äâ0.0001). CONCLUSION: Mepitel interventions significantly reduced RTOG grades and RISRAS scores, decreased the risk of moist desquamation, and shortened healing times for radiation-induced dermatitis in cancer patients. Further clinical studies are needed to better understand the relationship between Mepitel and radiation dermatitis in this patient population.</description>
    </item>
    <item>
      <title>#3 [75/100] Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC: A Systematic Review and Meta-Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41410931/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41410931/</guid>
      <dc:creator>Mastrolonardo EV, De Ravin E, Kaki PC, Estephan LE, Nunes K, Kenny H, Bridgham K, Tasoulas J, Koeneman SH, Goldman RA, et al.</dc:creator>
      <pubDate>Thu, 18 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important clinical question regarding the association between pathologic treatment response and survival in neoadjuvant immunotherapy for HNSCC, which could influence treatment practices, although it is based on phase 2 trials rather than large RCTs.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Mastrolonardo EV, De Ravin E, Kaki PC, Estephan LE, Nunes K, Kenny H, Bridgham K, Tasoulas J, Koeneman SH, Goldman RA, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.4573'&gt;10.1001/jamaoto.2025.4573&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-18&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41410931/'&gt;41410931&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: Numerous phase 2 trials have evaluated the efficacy of neoadjuvant immune checkpoint inhibition (ICI) for mucosal head and neck squamous cell carcinoma (HNSCC), using some degree of pathologic treatment response as a primary or secondary end point. However, whether pathologic treatment response is a meaningful surrogate end point for survival has yet to be determined. OBJECTIVE: To systematically assess the association between pathologic treatment response and overall survival (OS) and disease-free survival (DFS) after neoadjuvant ICI. DATA SOURCES: A systematic search of the PubMed, OVID Medline, Embase, CINAHL, and Cochrane databases was performed from January 1, 2000, through May 31, 2025. STUDY SELECTION: Peer-reviewed studies investigating neoadjuvant ICI for the treatment of mucosal HNSCC in patients 18 years and older were identified. Full-length English-language articles that presented pathologic treatment response and survival data (OS and/or DFS) and any association between the 2 were included. DATA EXTRACTION AND SYNTHESIS: Three blinded reviewers independently extracted study characteristics, pathologic treatment response data, and survival data, including hazard ratios (HRs) and CIs when available, according to PRISMA guideline. Data were compiled for statistical analysis to calculate DFS, OS, and HRs using a random-effects model. The I2 index was used to report data heterogeneity. MAIN OUTCOMES AND MEASURES: HRs for the association of pathologic treatment response with DFS and OS. RESULTS: Eleven trials involving 451 patients met inclusion criteria, with 368 patients included in this meta-analysis. Nine nonrandomized and 2 randomized studies were included, including 7 cohort studies, 2 randomized clinical trials, and 2 retrospective cohort studies, each with a different neoadjuvant ICI regimen. Pooled analysis demonstrated that overall (primary tumor‚Äâplus‚Äâlymph node) partial pathologic response (PPR; ‚â§50% residual viable tumor; HR, 0.53; 95% CI, 0.28-0.97; I2‚Äâ=‚Äâ2.1%) and major pathologic response (MPR; ‚â§10% residual viable tumor; HR, 0.34; 95% CI, 0.12-0.93; I2‚Äâ=‚Äâ0.0%) were both associated with improved DFS up to 2 years. PPR and MPR were not associated with improved OS. Nine of 11 studies were at low risk of bias. CONCLUSIONS AND RELEVANCE: Study findings suggest that overall PPR and MPR are associated with improved DFS. These data provide additional support for the potential use of pathologic treatment response as a surrogate for DFS after neoadjuvant ICI in resectable mucosal HNSCC.</description>
    </item>
    <item>
      <title>#4 [70/100] Greater Attention to Gingival Cancer and Floor of Mouth Cancer: Based on a Retrospective Analysis of Oral Cancer Across Different Subsites.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41424359/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41424359/</guid>
      <dc:creator>Li H, Ding Y, Wu Y, Fang Y, Li X, Shi W, Chen S, Yang A, Zhang J, Shi R, et al.</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large retrospective analysis of 885 patients with oral squamous cell carcinoma, identifying important survival differences based on tumor subsites, which could inform clinical understanding and management, though it lacks the prospective design and practice-changing implications of higher-impact studies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Li H, Ding Y, Wu Y, Fang Y, Li X, Shi W, Chen S, Yang A, Zhang J, Shi R, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70145'&gt;10.1002/hed.70145&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41424359/'&gt;41424359&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: The gingiva and floor of the mouth are distinct subsites, and oral squamous cell carcinoma (OSCC) originating in these locations warrants further indepth understanding. METHODS: This study enrolled patients with OSCC from 2000 to 2020, and analyzed the clinicopathological characteristics. Kaplan-Meier analysis compared overall survival (OS) and recurrence-free survival (RFS). Univariate analysis and multivariate Cox proportional hazards model examined the risk factors on survival outcomes. RESULTS: A total of 885 OSCC patients were included, with the most common tumor subsites: oral tongue (41.9%), gingiva (31.8%), and floor of mouth (16.0%). Gingival and floor of mouth showed a higher proportion of advanced stage (65.8%, 66.9%) and significantly poorer OS (3-year: 63.0%, 57.0%; 5-year: 49.8%, 37.3%) and RFS (3-year: 59.1%, 61.3%; 5-year: 55.5%, 57.0%). Neoadjuvant chemotherapy was associated with significantly reduced mortality in gingival cancer (HR‚Äâ=‚Äâ0.598), while tobacco exposure (HR‚Äâ=‚Äâ1.952) was associated with a significant increase in mortality in floor of mouth cancer. CONCLUSION: Gingival cancer and floor of mouth cancer have a worse prognosis, and thus require greater attention throughout the entire management process.</description>
    </item>
    <item>
      <title>#5 [70/100] Feasibility and Adherence to Home-Based Intensive Treatment Programs for Chronic Radiation-Associated Dysphagia in Head and Neck Cancer Survivors-The HIT-CRAD Trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41420436/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41420436/</guid>
      <dc:creator>Massonet H, Goeleven A, Nuyts S, Vergauwen A, Baudelet M, Duprez F, Tomassen P, Van den Steen L, Van Nuffelen G</dc:creator>
      <pubDate>Sat, 20 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The HIT-CRAD trial is a randomized controlled trial addressing an important clinical issue‚Äîchronic dysphagia in head and neck cancer survivors‚Äîdemonstrating feasibility and adherence to a novel home-based intervention, which could have significant implications for patient care.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Massonet H, Goeleven A, Nuyts S, Vergauwen A, Baudelet M, Duprez F, Tomassen P, Van den Steen L, Van Nuffelen G&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70136'&gt;10.1002/hed.70136&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-20&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41420436/'&gt;41420436&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: The HIT-CRAD trial (ISRCTN57028065) is the first to combine home-based non-invasive brain stimulation with high-volume strength and skill training over 8‚Äâweeks in patients with chronic radiation-associated dysphagia (CRAD) following primary (chemo)radiotherapy for head and neck cancer. METHODS: Fifty-four patients were randomized into three groups. Group 1 performed 8‚Äâweeks of strength training. Groups 2 and 3 combined 4‚Äâweeks of strength training with 4‚Äâweeks of skill training. Group 3 received high-definition transcranial direct current stimulation (HD-tDCS) during training. Group 2 received sham HD-tDCS. RESULTS: Overall adherence and exercise adherence remained above 75% across all groups. Home-based HD-tDCS proved safe and feasible, with mild to moderate side effects (tingling, itching, or burning). Median exercise performance levels for strength training exercises ranged from 94% to 100%. CONCLUSIONS: This study confirms the feasibility of high-volume strength and skill training with HD-tDCS in patients with C-RAD. Proactive adherence-supporting factors facilitate high adherence in this population. Both real and sham HD-tDCS proved safe, feasible, and well tolerated. TRIAL REGISTRATION: International Standard Randomized Controlled Trials Number (ISRCTN) registry ID ISRCTN57028065.</description>
    </item>
    <item>
      <title>#6 [70/100] The actual performance of ML/AI models in predicting radiation-induced toxicity in head and neck cancer: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41421773/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41421773/</guid>
      <dc:creator>Ugwu GC, Jalali F, Liu G, Li G, Langendijk JA, Alizadeh BZ</dc:creator>
      <pubDate>Thu, 18 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis evaluates the predictive accuracy of ML/AI models for radiation-induced toxicities in head and neck cancer, providing important insights into a growing area of research, though it lacks the robust sample size and direct clinical applicability of larger prospective studies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ugwu GC, Jalali F, Liu G, Li G, Langendijk JA, Alizadeh BZ&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2025.111350'&gt;10.1016/j.radonc.2025.111350&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-18&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41421773/'&gt;41421773&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;An increasing number of Artificial intelligence (AI) and machine learning (ML) models are being developed to predict radiation-induced toxicities (RITs) in patients with head and neck cancer (HNC). But their performance and reliability remain uncertain. This systematic review and meta-analysis evaluated the predictive accuracy and methodological quality of these models. We comprehensively searched PubMed, EMBASE, Web of Science, and the Cochrane Library to identify studies reporting on ML/AI models for predicting RITs in HNC patients. Eligible studies were assessed for bias risk using the PROBAST tool, and key performance metrics, including the area under the receiver operating curve (AUROC), were extracted. A hierarchical multilevel meta-analysis was performed to estimate pooled AUC values, and subgroup analyses explored the influence of study characteristics on model performance. A total of 67 studies with a total of 568 models were included, showing moderate discriminatory power of ML/AI models, with a pooled AUC = 0.76; 95‚ÄØ% CI: 0.73-0.78. Nonetheless, substantial heterogeneity was observed across studies. Incorporating imaging biomarkers significantly improved model performance. Prospective and internal validation showed comparable performance; external validation shows true generalizability. The predominance of retrospective designs and variability in predictor selection may have introduced bias, affecting model reliability and generalisability. ML/AI models hold promise for predicting RITs in HNC patients, but methodological constraints limit their applicability. Standardised and transparent reporting of model development and validation processes is vital for improving comparability among studies. Future research should explore hybrid modelling methods and the integration of clinical, dosimetric, radiomic, and genomic data to boost predictive accuracy.</description>
    </item>
    <item>
      <title>#7 [70/100] Pembrolizumab in Head and Neck Cancer-Promise and Price.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41410927/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41410927/</guid>
      <dc:creator>Miller LE, Rocco JW, Rathi VK</dc:creator>
      <pubDate>Thu, 18 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses pembrolizumab in head and neck cancer, which is a relevant and important topic, but without specific details on study design or outcomes, it appears to be a review or commentary rather than a primary research article, limiting its impact.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Miller LE, Rocco JW, Rathi VK&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.4624'&gt;10.1001/jamaoto.2025.4624&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-18&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41410927/'&gt;41410927&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#8 [70/100] Differences in Survival Following Surgery Versus Chemoradiotherapy for Clinical Stage T4a Laryngeal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41403196/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41403196/</guid>
      <dc:creator>Fu BJ, Potter AL, Pipkorn P, Kraimer KL, Chen MM, Rajasekaran K, Yang CJ, Lee JJ</dc:creator>
      <pubDate>Tue, 16 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes a large retrospective cohort analysis with over 3500 patients, providing important insights into survival outcomes between surgery and chemoradiotherapy for a specific cancer stage, which could influence treatment decisions.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Fu BJ, Potter AL, Pipkorn P, Kraimer KL, Chen MM, Rajasekaran K, Yang CJ, Lee JJ&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70114'&gt;10.1002/hed.70114&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41403196/'&gt;41403196&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Although laryngeal cancer incidence has declined in the United States, case fatality has risen. The survival equivalence of surgery versus chemoradiotherapy (CRT) for cT4a laryngeal squamous cell carcinoma (LSCC) remains uncertain. METHODS: We conducted a retrospective cohort study of cT4a LSCC patients treated with curative-intent surgery or CRT using the National Cancer Database (2010-2021). Those receiving neoadjuvant or palliative therapy, or with distant metastases were excluded. Survival was assessed using Kaplan-Meier and Cox models after 1:1 propensity score matching. RESULTS: Among 3569 patients (mean age 61.0, 708 female), 2437 (68.3%) underwent surgery while 1132 (31.7%) received CRT. In the matched cohort (n‚Äâ=‚Äâ452 per arm), median survival was 52.8 (95% CI: 45.6-62.4) versus 37.6 (95% CI: 29.2-45.4) months for surgery versus CRT. Adjusted HR for CRT relative to surgery was 1.26 (95% CI: 1.02-1.57). CONCLUSIONS: Surgery was associated with improved overall survival compared with definitive CRT in patients with T4a LSCC.</description>
    </item>
    <item>
      <title>#9 [65/100] Tumor Vascular Area Quantification Predicts Survival Outcomes in Oral Squamous Cell Carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41428856/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41428856/</guid>
      <dc:creator>Yu L, Li F, Wang J, Xue Y, Zeng T, Huang X, Zhang L, Deng R, Wang S</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The study presents a novel method for quantifying tumor vascular area in oral squamous cell carcinoma and demonstrates its association with survival outcomes, but it is based on relatively small cohorts and lacks the robustness of larger prospective studies or randomized trials.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Yu L, Li F, Wang J, Xue Y, Zeng T, Huang X, Zhang L, Deng R, Wang S&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral diseases | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1111/odi.70174'&gt;10.1111/odi.70174&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41428856/'&gt;41428856&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Cancer cells remodel blood vessels to create a tumor-supportive environment; however, the spatial distribution of these vessels and their prognostic significance in oral squamous cell carcinoma (OSCC) remain poorly defined. METHODS: We established an open-source pipeline to quantify vascular area (VA) in both the inner tumor (InT) and invasive tumor front (ITF) regions from CD31-stained whole-slide images (discovery cohort, n‚Äâ=‚Äâ66). The associations between VA and patient survival were assessed via univariate and multivariate analyses. Findings were validated in an independent cohort (n‚Äâ=‚Äâ70) immunostained with CD34. RESULTS: VA was significantly higher in the InT region compared to the ITF (p‚Äâ=‚Äâ0.0079). A higher VA in the ITF was independently associated with favorable overall survival (discovery: HR 0.28, 95% CI 0.11-0.73, p‚Äâ=‚Äâ0.009; validation: HR 0.18, 95% CI 0.07-0.47, p‚Äâ&lt;‚Äâ0.001) and disease-free survival (discovery: HR 0.34, 95% CI 0.14-0.81, p‚Äâ=‚Äâ0.015; validation: HR 0.25, 95% CI¬†0.11-0.53, p‚Äâ&lt;‚Äâ0.001). CONCLUSION: Our findings provide the first evidence that high VA in the ITF is associated with a better prognosis in OSCC.</description>
    </item>
    <item>
      <title>#10 [65/100] Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41421245/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41421245/</guid>
      <dc:creator>Liu Q, Wei JN, Zhou JY, Zhang CR, Ke LR, Lu N, Deng Y, Kuang YW, Hua YC, Wang MW, et al.</dc:creator>
      <pubDate>Fri, 19 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a retrospective analysis with a novel scoring system for MRI-detected lymph node features in nasopharyngeal carcinoma, which may have clinical implications for N classification, but lacks the robustness of a large prospective study or randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Liu Q, Wei JN, Zhou JY, Zhang CR, Ke LR, Lu N, Deng Y, Kuang YW, Hua YC, Wang MW, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Oral oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.oraloncology.2025.107825'&gt;10.1016/j.oraloncology.2025.107825&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-19&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41421245/'&gt;41421245&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: To develop a retropharyngeal lymph node (RLN)-based scoring system using anatomical features and to evaluate its utility in optimizing N classification in patients with nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: This retrospective cohort study included patients with nonmetastatic NPC treated at two tertiary referral cancer centers in China between January 2012 and December 2018. Univariate and multivariate analyses were used to evaluate the association between MRI-based RLN features and multiple survival endpoints. A simplified RLN risk scoring (RRS) system (incorporating RLN multiplicity, MID, adENE and CNN) was developed in SYSUCC cohort and validated in the GMUCH cohort. A new N classification system was proposed and compared with the 9th edition of AJCC N staging system using C-index. RESULTS: Positive RLNs were observed in 68.3¬†% of all patients, including 66.7¬†% (690/1035) in the SYSUCC cohort and 72.0¬†% (340/472) in the GMUCH cohort. High RRS (defined as RRS &gt; 2) was independently associated with worse OS (hazard ratio [HR], 2.22; 95¬†% CI, 1.56-3.15, P¬†&lt;¬†0.001), PFS (HR, 2.45; 95¬†% CI, 1.87-3.20, P¬†&lt;¬†0.001), DMFS (HR, 2.71; 95¬†% CI, 1.88-3.91, P¬†&lt;¬†0.001), and RFS (HR, 2.20; 95¬†% CI, 1.51-3.20, P¬†&lt;¬†0.001). The proposed N classification system incorporated high RRS as a criterion for N3 disease, demonstrated higher C-index values compared with the 9th edition AJCC staging system for OS (0.666 vs 0.659), PFS (0.659 vs 0.639), DMFS (0.682 vs 0.663), and RFS (0.644 vs 0.629). CONCLUSIONS: High RRS was strongly correlated with inferior survival outcomes in NPC patients. Integrating high RRS into the current staging system by reclassifying these patients as N3 might improve prognostic stratification and offer more precise treatment guidance.</description>
    </item>
  </channel>
</rss>
